Credit Suisse Starts Kite Pharma (KITE) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cowen Starts Kite Pharma (KITE) at Outperform
July 15, 2014 7:45 AM EDTCowen initiated coverage on Kite Pharma (NASDAQ: KITE) with an Outperform rating.
For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.
Shares of Kite Pharma closed at $24.05 yesterday.
... MoreStifel Nicolaus Starts Kite Pharma (KITE) at Buy
July 15, 2014 7:44 AM EDTStifel Nicolaus initiated coverage on Kite Pharma (NASDAQ: KITE) with a Buy rating and a price target of $31.00.
For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.
Shares of Kite Pharma closed at $24.05 yesterday.
... MoreJefferies Starts Kite Pharma (KITE) at Buy
July 15, 2014 6:41 AM EDTJefferies initiates coverage on Kite Pharma (NASDAQ: KITE) with a Buy rating and a price target of $35.00.
Analyst Biren Amin comments, "KITE shares hold significant promise based on PI/II data with KTE-C19 observing robust responses in... More
